Gender differences in switching biologics in PsA pts Women had higher biologic switch rates, mainly due to lack of efficacy Other gender specific factors include gestational reasons and different sociodemographic features @RheumNow #ACR23 Abs#2247 https://t.co/mLm183fCBw

Be a SpA (and PsA) Sleuth! My article is your call to arms for better understanding and discovery of IBD in our inflammatory back pain patients. Consider fecal calprotectin AND robust ROS as your magnifying glass! #ACR23 @rheumnow https://t.co/OnQDEWgIWM

Bimekizumab is Coming… in 3rd Place Nearly two dozen bimekizumab abstracts will be featured at #ACR23 and it recently received authorization in Europe and the US for psoriasis. https://t.co/i2ptDnGr4a https://t.co/rZC6IORm5E

• Bimekizumab is Coming… in Third Place | RheumNow

#irAE Baseline immune suppression does NOT protect against worsening synovitis flares when using check point inhibitors in Pts with established #inflammatory #arthritis #ACRbest #ACR23 @ACRheum @RheumNow abst1075 Data from #CanRIO database https://t.co/lOCf8Tbgta

#ACR23 Abs #2199 large RL study: SEC retention rates after 4 yrs approx. 50% in axSpA and PsA pts. Bio-naïve pts had higher retention, remission & response rates than pts with prior b/tsDMARD exposure, particularly in axSpA. https://t.co/Eq5BwILK3D @rheumnow https://t.co/slho6yAwtQ

PtGA and PhGA were aligned in most encounters in PsA. PtGA >PhGA disagreement was driven by pain, fatigue, and physical health being weighed more by Pts than Phs. PROs matter! #ACR23 Abs #2234 https://t.co/0r7gjx0JS6 @rheumnow https://t.co/BuGDicwBiB